Cardioxane (ADR-529) is a cardio-protective drug.

HTRF assay: Homogeneous time-resolved fluorescence (HTRF) assay measures the signal generated by 2 components when they are in close proximity. The p53–MDM2 binding assay uses a biotinylated peptide derived from the MDM2-binding domain of p53 and a truncated N-terminal portion of recombinant human GST-tagged MDM2 protein containing the p53-binding domain. Proteins for crystal structure studies are expressed in E. coli strain BL21 using the helper plasmid pUBS 520 coding for the lacIq repressor and the rare tRNAArg [AGA/AGG]. For crystallization, the frozen protein is thawed and concentrated to 9.8 mg/mL using a Centricon concentrator (3,000 MW cutoff). The complex is then formed by combining the protein with a slight molar excess of the inhibitor (stock solution is 100 mM in DMSO) and this solution is allowed to sit for 4 hours at 4°C. Cryopreserved crystals are used to collect diffraction data on beamline X8C at the National Synchrotron Light Source at Brookhaven National Laboratory.

右雷佐生盐酸盐, ICRF-187 hydrochloride, ICRF-187, Dexrazoxane HCl, Cardioxane hydrochloride, ADR-529 Hydrochloride, ADR-529

H2O: 55 mg/mL (180.49 mM), Sonication is recommended.

DMSO: 50 mg/mL (164.08 mM), Sonication is recommended.

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (8.2 mM), Sonication is recommended.